Keytruda

국가: 유럽 연합

언어: 리투아니아어

출처: EMA (European Medicines Agency)

유효 성분:

Pembrolizumab

제공처:

Merck Sharp & Dohme B.V.

ATC 코드:

L01FF02

INN (International Name):

pembrolizumab

치료 그룹:

Antinavikiniai vaistai

치료 영역:

Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Urologic Neoplasms; Endometrial Neoplasms

치료 징후:

MelanomaKeytruda as monotherapy is indicated for the treatment of adults and adolescents aged 12 years and older with advanced (unresectable or metastatic) melanoma. Keytruda as monotherapy is indicated for the adjuvant treatment of adults and adolescents aged 12 years and older with Stage IIB, IIC, or with Stage III melanoma and lymph node involvement who have undergone complete resection. Non small cell lung carcinoma (NSCLC)Keytruda as monotherapy is indicated for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum based chemotherapy (for selection criteria, see section 5. Keytruda as monotherapy is indicated for the first line treatment of metastatic non small cell lung carcinoma in adults whose tumours express PD L1 with a ≥ 50% tumour proportion score (TPS) with no EGFR or ALK positive tumour mutations. Keytruda, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non squamous non small cell lung carcinoma in adults whose tumours have no EGFR or ALK positive mutations. Keytruda, in combination with carboplatin and either paclitaxel or nab paclitaxel, is indicated for the first line treatment of metastatic squamous non small cell lung carcinoma in adults. Keytruda  as monotherapy is indicated for the treatment of locally advanced or metastatic non small cell lung carcinoma in adults whose tumours express PD L1 with a ≥ 1% TPS and who have received at least one prior chemotherapy regimen. Pacientams su EGFR ar ŠARMINIAI teigiamas navikas mutacijų, taip pat turėtų būti gautas tikslinis gydymas prieš gaunant KEYTRUDA. Classical Hodgkin lymphoma (cHL)Keytruda as monotherapy is indicated for the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option. Urothelial carcinomaKeytruda as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum containing chemotherapy. Keytruda as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin containing chemotherapy and whose tumours express PD L1 with a combined positive score (CPS) ≥ 10. Head and neck squamous cell carcinoma (HNSCC)Keytruda, as monotherapy or in combination with platinum and 5 fluorouracil (5 FU) chemotherapy, is indicated for the first line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express PD L1 with a CPS ≥ 1. Keytruda as monotherapy is indicated for the treatment of recurrent or metastatic head and neck squamous cell carcinoma in adults whose tumours express PD L1 with a ≥ 50% TPS and progressing on or after platinum containing chemotherapy. Renal cell carcinoma (RCC)Keytruda, in combination with axitinib, is indicated for the first line treatment of advanced renal cell carcinoma in adults. Keytruda  as monotherapy is indicated for the adjuvant treatment of adults with renal cell carcinoma at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions (for selection criteria, please see section 5. Microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) cancersColorectal cancer (CRC)Keytruda as monotherapy is indicated for theadults with MSI-H or dMMR colorectal cancer in the following settings:first line treatment of metastatic microsatellite instability high (MSI H) or mismatch repair deficient (dMMR) colorectal cancer in adults;treatment of unresectable or metastatic colorectal cancer after previous fluoropyrimidine based combination therapy.  Non-colorectal cancersKeytruda as monotherapy is indicated for the treatment of the following MSI H or dMMR tumours in adults with:advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum containing therapy in any setting and who are not candidates for curative surgery or radiation;unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy. Oesophageal carcinomaKeytruda, in combination with platinum and fluoropyrimidine based chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastroesophageal junction adenocarcinoma, in adults whose tumours express PD L1 with a CPS ≥ 10. Triple negative breast cancer (TNBC)Keytruda, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early stage triple negative breast cancer at high risk of recurrence. Keytruda, in combination with chemotherapy, is indicated for the treatment of locally recurrent unresectable or metastatic triple negative breast cancer in adults whose tumours express PD L1 with a CPS ≥ 10 and who have not received prior chemotherapy for metastatic disease. Endometrial carcinoma (EC)Keytruda, in combination with lenvatinib, is indicated for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum containing therapy in any setting and who are not candidates for curative surgery or radiation. Cervical cancerKeytruda, in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD L1 with a CPS ≥ 1. Gastric or gastro-oesophageal junction (GEJ) adenocarcinomaKEYTRUDA, in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS ≥ 1.

제품 요약:

Revision: 54

승인 상태:

Įgaliotas

승인 날짜:

2015-07-17

환자 정보 전단

1
I PRIEDAS
PREPARATO CHARAKTERISTIKŲ SANTRAUKA
2
1.
VAISTINIO PREPARATO PAVADINIMAS
KEYTRUDA 25
mg/ml koncentratas infuziniam tirpalui
2.
KOKYBINĖ IR KIEKYBINĖ SUDĖTIS
Viename 4
ml koncentrato
flakone yra 100
mg pembrolizumabo.
Kiekviename
koncentrato mililitre yra 25
mg pembrolizumabo.
Pembrolizumabas yra humanizuotas monokloninis antikūnas (IgG4/kappa
izotipas su
stabilizuojančiąja sekos pakaita Fc regione) prieš programuotos
ląstelės žūties antigeną
-1 (angl. anti-
programmed cel
l death-1 (PD-1)
), pagamintas kininio žiurkėn
uk
o patelės kiaušidžių ląstelėse
rekombinantinės DNR technologijos būdu.
Visos pagalbinės medžiagos išvardytos 6.1
skyriuje.
3.
FARMACINĖ FORMA
Koncentratas infuziniam tirpalui
.
Skaidrus arba šiek tiek opal
inis, bespalvis ar gelsvas tirpalas, kurio pH
5,2
–
5,8.
4.
KLINIKINĖ INFORMACIJA
4.1
Terapinės indikacijos
Melanoma
Monoterapija KEYTRUDA skirta suaugusiems pacientams
bei 12
metų ir vyresniems paaugliams
išplitusios
(nerezekuotinos arba metastazavus
ios) melanomos gydymui.
Monoterapija KEYTRUDA skirta adjuvantiniam gydymui suaugusiems
pacientams bei 12
metų ir
vyresniems paaugliams
, kuriems nustatyta
IIB, IIC arba
III stadij
ų
melanoma ir kuriems buvo atlikta
visiška rezekcija (žr. 5.1
skyrių).
Nesmu
lkiųjų ląstelių plaučių vėžys (NSLPV)
Monoterapija KEYTRUDA skirta nesmulkiųjų ląstelių plaučių
vėžiu sergančių suaugusiųjų, kuriems
yra didelė vėžio recidyvo rizika po radikalios rezekcijos ir
chemoterapijos platinos vaistiniais
preparatais, adjuvantinia
m gydymui (atrankos kriterijai nurodyti 5.1
skyriuje).
Monoterapija
KEYTRUDA yra skirta metastazavusio nesmulkiųjų ląstelių plaučių
vėžio pirmos eilės
gydymui suaugusiems pacientams, kurių navikuose PD
-
L1 raiška naviko proporcijos balais (angl.
tumour pro
portion score (
TPS)
) yra ≥
50
%, o EGFR ar ALK naviko mutacijų nenustatyta.
KEYTRUDA derin
ant su
chemoterapija pemetreksedu ir platinos vaistiniais preparatais
skirtas
metastazavusio neplokščialąste

제품 특성 요약

1
I PRIEDAS
PREPARATO CHARAKTERISTIKŲ SANTRAUKA
2
1.
VAISTINIO PREPARATO PAVADINIMAS
KEYTRUDA 25
mg/ml koncentratas infuziniam tirpalui
2.
KOKYBINĖ IR KIEKYBINĖ SUDĖTIS
Viename 4
ml koncentrato
flakone yra 100
mg pembrolizumabo.
Kiekviename
koncentrato mililitre yra 25
mg pembrolizumabo.
Pembrolizumabas yra humanizuotas monokloninis antikūnas (IgG4/kappa
izotipas su
stabilizuojančiąja sekos pakaita Fc regione) prieš programuotos
ląstelės žūties antigeną
-1 (angl. anti-
programmed cel
l death-1 (PD-1)
), pagamintas kininio žiurkėn
uk
o patelės kiaušidžių ląstelėse
rekombinantinės DNR technologijos būdu.
Visos pagalbinės medžiagos išvardytos 6.1
skyriuje.
3.
FARMACINĖ FORMA
Koncentratas infuziniam tirpalui
.
Skaidrus arba šiek tiek opal
inis, bespalvis ar gelsvas tirpalas, kurio pH
5,2
–
5,8.
4.
KLINIKINĖ INFORMACIJA
4.1
Terapinės indikacijos
Melanoma
Monoterapija KEYTRUDA skirta suaugusiems pacientams
bei 12
metų ir vyresniems paaugliams
išplitusios
(nerezekuotinos arba metastazavus
ios) melanomos gydymui.
Monoterapija KEYTRUDA skirta adjuvantiniam gydymui suaugusiems
pacientams bei 12
metų ir
vyresniems paaugliams
, kuriems nustatyta
IIB, IIC arba
III stadij
ų
melanoma ir kuriems buvo atlikta
visiška rezekcija (žr. 5.1
skyrių).
Nesmu
lkiųjų ląstelių plaučių vėžys (NSLPV)
Monoterapija KEYTRUDA skirta nesmulkiųjų ląstelių plaučių
vėžiu sergančių suaugusiųjų, kuriems
yra didelė vėžio recidyvo rizika po radikalios rezekcijos ir
chemoterapijos platinos vaistiniais
preparatais, adjuvantinia
m gydymui (atrankos kriterijai nurodyti 5.1
skyriuje).
Monoterapija
KEYTRUDA yra skirta metastazavusio nesmulkiųjų ląstelių plaučių
vėžio pirmos eilės
gydymui suaugusiems pacientams, kurių navikuose PD
-
L1 raiška naviko proporcijos balais (angl.
tumour pro
portion score (
TPS)
) yra ≥
50
%, o EGFR ar ALK naviko mutacijų nenustatyta.
KEYTRUDA derin
ant su
chemoterapija pemetreksedu ir platinos vaistiniais preparatais
skirtas
metastazavusio neplokščialąste